JP2025511187A5 - - Google Patents

Info

Publication number
JP2025511187A5
JP2025511187A5 JP2024558023A JP2024558023A JP2025511187A5 JP 2025511187 A5 JP2025511187 A5 JP 2025511187A5 JP 2024558023 A JP2024558023 A JP 2024558023A JP 2024558023 A JP2024558023 A JP 2024558023A JP 2025511187 A5 JP2025511187 A5 JP 2025511187A5
Authority
JP
Japan
Prior art keywords
seq
target
binding protein
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/017130 external-priority patent/WO2023192606A2/en
Publication of JP2025511187A publication Critical patent/JP2025511187A/ja
Publication of JP2025511187A5 publication Critical patent/JP2025511187A5/ja
Pending legal-status Critical Current

Links

JP2024558023A 2022-04-01 2023-03-31 Ｃｄ３結合タンパク質及びその使用方法 Pending JP2025511187A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326668P 2022-04-01 2022-04-01
US63/326,668 2022-04-01
PCT/US2023/017130 WO2023192606A2 (en) 2022-04-01 2023-03-31 Cd3-binding proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025511187A JP2025511187A (ja) 2025-04-15
JP2025511187A5 true JP2025511187A5 (enExample) 2026-04-08

Family

ID=86185147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024558023A Pending JP2025511187A (ja) 2022-04-01 2023-03-31 Ｃｄ３結合タンパク質及びその使用方法

Country Status (5)

Country Link
US (1) US20250230239A1 (enExample)
EP (1) EP4504782A2 (enExample)
JP (1) JP2025511187A (enExample)
CN (1) CN119278215A (enExample)
WO (1) WO2023192606A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
CA2984892A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
MY200695A (en) 2016-11-03 2024-01-11 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
WO2019046652A1 (en) 2017-08-30 2019-03-07 Cytomx Therapeutics, Inc. ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019165143A1 (en) 2018-02-21 2019-08-29 Cytomx Therapeutics, Inc. Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
JP2021518603A (ja) 2018-03-20 2021-08-02 シートムエックス セラピューティクス，インコーポレイテッド 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
WO2019195535A1 (en) * 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
WO2019213444A1 (en) 2018-05-02 2019-11-07 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
US20220023439A1 (en) 2018-11-02 2022-01-27 Cytomx Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
US20220226514A1 (en) 2019-05-17 2022-07-21 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
WO2020252349A1 (en) 2019-06-13 2020-12-17 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
EP3983440A1 (en) 2019-06-13 2022-04-20 CytomX Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
JP2022548310A (ja) 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
EP4087855A1 (en) 2020-01-06 2022-11-16 CytomX Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
JP2023521384A (ja) 2020-04-09 2023-05-24 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗体を含む組成物
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2021087429A5 (enExample)
JP2023526428A5 (enExample)
JP5011277B2 (ja) ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
JP2019513014A5 (enExample)
US9540618B2 (en) Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CN103242451B (zh) 基于免疫球蛋白的多价生物活性装配体
JP2025511187A5 (enExample)
TW201930341A (zh) 釋放片段及包含其之結合組合物
Lu et al. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment
JP2009517337A (ja) 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
JP7832926B2 (ja) 制約され、条件付きで活性化された結合タンパク質
CN104321081A (zh) 免疫治疗分子和用途
US20240327538A1 (en) Compositions targeting prostate-specific membrane antigen and methods for making and using the same
JP2025511713A5 (enExample)
US20250188172A1 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
JP2025511190A5 (enExample)
JP2024531338A5 (enExample)
RU2020123264A (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
JP7855148B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法
US20170121692A1 (en) Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses
KR20260011227A (ko) 마스킹된 항체, 라이브러리 및 이의 사용 방법
WO2026024863A2 (en) Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
HK1135901A (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses